

**Main Questions and Answers Related to
the Second Quarter Results of Fiscal Year Ending March 2022**

Q: Tell us about the progress toward the plan regarding Q2 results.

A: In the entire business, we exceeded the plan for both revenue and operating profit. Regarding revenue, Healthcare segment exceeded the plan mainly due to Medical Systems business, demand for mobile X-ray systems and portable ultrasound diagnostic devices increased more than expected due to the supplementary budget related to COVID-19 in Japan, and for Life Science business, its revenue increased due to solid sales of cell culture media. Materials and Imaging segments also exceeded the plan. In Materials segment, revenue of Electronic Materials business rose as sales of a wide range of products, fared well in line with increasing demand for semiconductors, and Display Materials business also kept good sales due to the strong demand under COVID-19. In Business Innovation segment, we fell short of the plan mainly due to the impact of COVID-19 pandemic in Japan and Asia-Pacific region and delays in equipment supply/installation impacted by tight supply of semiconductors. Regarding operating profit, despite Business Innovation segment could not reach the plan mainly due to higher costs for parts, we exceeded the overall plan thanks to the growth in revenue.

Q: Tell us about the contribution of newly consolidated FUJIFILM Healthcare Corporation (FHC) to Medical Systems business.

A: As FHC became a part of FUJIFILM, collaboration of both companies is proceeding smoothly. In the manufacturing area, we are increasing our competitiveness by coordinating cost reductions and unifying development platforms. Similarly in the sales area, a strong global sales network is being established by integrating sales companies in North America and conducting sales, installation, and maintenance by leveraging both sales channels.

Q: Tell us about the progress toward the FY2021 plan for Bio CDMO business.

A: Revenue result for the first half was slightly higher than the plan due to the impact of exchange rates and total revenue for FY2021 is expected to achieve the target of 140 billion yen.